Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Improving and streamlining clinical trials in multiple myeloma

Pieter Sonneveld • 25 Aug 2022
IMS 2022
Multiple Myeloma Bortezomib Daratumumab Lenalidomide
PERSEUS

Pieter Sonneveld, MD, PhD, Erasmus Medical Center Cancer Institute, Rotterdam, Netherlands, shares the highlights of a session aiming to improve and streamline clinical trials in multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Pieter Sonneveld

2:54
The PERSEUS trial: primary results of D-VRd vs VRd in newly diagnosed, transplant eligible MM
Pieter Sonneveld • 11 Dec 2023
Reaching a cure for multiple myeloma
Gareth Morgan et al. • 15 Apr 2023
1:57
The benefit of double autologous transplantation in multiple myeloma patient subgroups
Pieter Sonneveld • 24 Oct 2022
1:27
Do CAR-T therapies play a role in earlier lines of therapy in multiple myeloma?
Pieter Sonneveld • 24 Oct 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals